Published in Cancer on September 01, 1989
Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer (2011) 1.52
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer (2006) 1.30
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer (2009) 1.20
Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer (2010) 1.16
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer (2013) 1.12
Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. Support Care Cancer (2010) 1.11
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer (2010) 1.06
Antiemetic study design: desirable objectives, stratifications and analyses. Br J Cancer Suppl (1992) 1.05
Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes. Support Care Cancer (2005) 1.03
Myths and realities of antiemetic treatment. Br J Cancer Suppl (1992) 0.87
Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer (2011) 0.87
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer (2008) 0.83
A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients. Cancer Res Treat (2013) 0.80
Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting. J Adv Pharm Technol Res (2012) 0.80
Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study. Support Care Cancer (2012) 0.76
Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. Pharmacogenomics J (2016) 0.76
[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research]. Med Klin (Munich) (1998) 0.75
Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting. Toxicol Res (2012) 0.75
Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy. Medicine (Baltimore) (2016) 0.75
A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. Support Care Cancer (2017) 0.75
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood (2000) 1.79
Effectiveness of continuous wound infusion of 0.5% ropivacaine by On-Q pain relief system for postoperative pain management after open nephrectomy. Br J Anaesth (2008) 1.70
Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys (1998) 1.68
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol (2003) 1.64
Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol (1999) 1.53
Use of discriminant analysis to assess disease activity in pulmonary tuberculosis with a panel of specific and nonspecific serum markers. Am J Clin Pathol (1994) 1.52
Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med (2000) 1.47
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res (1997) 1.42
Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. J Clin Oncol (1992) 1.42
Does low-molecular-weight heparin influence cancer-related mortality? Ann Oncol (2006) 1.38
The effect of extend of caval resection in the treatment of inferior vena cava leiomyosarcoma. Anticancer Res (1998) 1.22
Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood (1999) 1.15
Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology (2010) 1.15
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol (2010) 1.14
Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. J Clin Oncol (1998) 1.10
Local recurrence after curative resection for colorectal cancer: frequency, risk factors and treatment. J Surg Oncol Suppl (1991) 1.10
Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer (2000) 1.08
Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol (1998) 1.06
Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol (2004) 1.04
Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol (2010) 0.99
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol (2011) 0.97
Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer (1989) 0.96
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol (2003) 0.95
The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol (1989) 0.93
Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol (2000) 0.92
Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J Clin Oncol (1991) 0.90
Tumor progression in human malignant melanoma is associated with changes in alpha 6/beta 1 laminin receptor. Int J Cancer (1991) 0.88
Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Am J Clin Oncol (2000) 0.88
DNA ploidy, proliferative index, and epidermal growth factor receptor: expression and prognosis in patients with gastric cancers. Lab Invest (1995) 0.87
Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. Anticancer Drugs (2000) 0.86
Early post-operative MRI: correlation with progression-free survival and overall survival time in malignant gliomas. J Exp Clin Cancer Res (2006) 0.85
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. Ann Oncol (2005) 0.84
Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother (1999) 0.83
HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters. J Exp Clin Cancer Res (2003) 0.83
Multivariate analysis of a tissue CEA, TPA, and CA 19.9 quantitative study in colorectal cancer patients. A preliminary finding. Dis Colon Rectum (1989) 0.83
Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol (1999) 0.83
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer (2006) 0.82
Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma. J Exp Clin Cancer Res (2003) 0.82
Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol (2007) 0.82
DNA ploidy, proliferative index and EGF-R status in 130 cases of resected gastric cancer--a multivariate analysis. Hepatogastroenterology (1997) 0.81
Detection of Helicobacter pylori carriers by discriminant analysis of urea and pH levels in gastric juices. J Clin Pathol (1991) 0.81
Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol (2011) 0.81
Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis. Eur J Surg Oncol (2000) 0.81
Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Ann Oncol (1993) 0.81
The application of hyperthermia in regional chemotherapy. Semin Surg Oncol (1998) 0.80
Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women. Breast Cancer Res Treat (1999) 0.80
Prognostic value of bone marrow histology in chronic lymphocytic leukemia. A study of 335 untreated cases from a single institution. Haematologica (1995) 0.80
Prevalence of intestinal metaplasia in the distal esophagus in patients endoscopically suspected for short Barrett's esophagus. J Exp Clin Cancer Res (2006) 0.80
120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study. In Vivo (2007) 0.80
Acute leukaemia in patients treated for Hodgkin's disease. Br J Haematol (1984) 0.80
Transurethral resection of the prostate and metastatic prostate cancer. Cancer (1991) 0.79
Sentinel node biopsy in cutaneous melanoma: correlations between melanoma prognostic factors and sentinel node status. J Exp Clin Cancer Res (2007) 0.78
Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study. Semin Oncol (1991) 0.78
Endoscopic follow-up in resected colorectal cancer patients. J Exp Clin Cancer Res (2000) 0.78
Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck. Eur J Cancer (1994) 0.78
A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer (1989) 0.78
Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study. J Exp Clin Cancer Res (2005) 0.78
High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Br J Haematol (1990) 0.78
Chemotherapy-induced amenorrhea in early breast cancer. Ann Oncol (2005) 0.78
Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome. J Chemother (2005) 0.78
Factorial design for randomized clinical trials. Ann Oncol (2006) 0.78
Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. Am J Clin Oncol (1989) 0.77
[Peritonectomy and chemohyperthermia in the treatment of peritoneal carcinomatosis: learning curve]. Suppl Tumori (2006) 0.77
Personality, inner experience and compliance in advanced cancer patients treated with external pumps. J Infus Chemother (1995) 0.77
Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. J Clin Oncol (1989) 0.77
Neoadjuvant chemotherapy in previously untreated patients with advanced head and neck squamous cell cancer. Cancer (1988) 0.77
High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients. J Exp Clin Cancer Res (2006) 0.77
Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer. Eur J Cancer (1995) 0.77
N-methylformamide affects spontaneous metastases of 3LL lines and increases natural killer activity of tumor-bearing mice. Clin Exp Metastasis (1990) 0.77
Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. Cancer (2001) 0.77
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck. Ann Oncol (1994) 0.76
Hot-flashes in breast cancer survivors: effectiveness of low-dosage fluoxetine. A pilot study. J Exp Clin Cancer Res (2005) 0.76
Flow cytometric analysis of ploidy in colorectal cancer: a multicentric experience. Br J Cancer (1993) 0.76
The role of multiploidy as unfavorable prognostic variable in colorectal cancer. Anticancer Res (1998) 0.76
Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. Urology (1997) 0.76
The Italian experience on interferon as maintenance treatment in multiple myeloma: ten years after. Blood (1998) 0.76
Nerve-sparing surgery in 302 resectable rectosigmoid cancer patients: genitourinary morbidity and 10-year survival. Dis Colon Rectum (1994) 0.76
Comparative analysis of CEA and SCC serum markers with IAP in human lung cancer. Int J Biol Markers (1989) 0.75
Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening? Gut (2005) 0.75
The role of the administration time of prophylactic antibiotic therapy in colorectal cancer surgery: a review of 6,069 patients from 36 randomized clinical trials. Ann Ital Chir (1994) 0.75
Fractional incorporation of radionucleotides, a marker of in vitro tumor cell chemosensitivity in colorectal cancer. Oncology (1991) 0.75
Extended criteria liver donation and transplant recipient consent: the European experience. Transplant Proc (2011) 0.75
Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma. Ann Oncol (1992) 0.75
Flow cytometric analysis of DNA content and cell kinetics in colorectal carcinoma. Anticancer Res (1993) 0.75
Hyperthermic antiblastic perfusion in the treatment of local recurrence or "in-transit" metastases of limb melanoma. Semin Surg Oncol (1992) 0.75
High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer: a pilot study. Cancer Invest (1994) 0.75
Cisplatin-induced peripheral neurotoxicity: relationship to dose intensity. Ann Oncol (1991) 0.75
A preliminary European Liver and Intestine Transplant Association-European Liver Transplant Registry study on informed recipient consent and extended criteria liver donation. Transplant Proc (2013) 0.75
Evaluation of the response to chemotherapy in patients affected with small cell lung cancer using discriminant analysis: a preliminary report. Q J Nucl Med (1995) 0.75
Radical surgery in rectal cancer patients: what does it mean today? J Surg Oncol Suppl (1991) 0.75
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol (2017) 0.75
Improved local control and survival with the "sandwich" technique of pelvic radiotherapy for resectable rectal cancer. A retrospective, multivariate analysis. Dis Colon Rectum (1994) 0.75
Thermochemotherapy for soft tissue sarcomas. Cancer Treat Res (1991) 0.75
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer (1993) 0.75
Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden? Ann Oncol (2005) 0.75
Definitive radiation therapy for localized prostatic adenocarcinoma. Int J Radiat Oncol Biol Phys (1991) 0.75